December 19, 2017 –
Naiyer A. Rizvi, MD, director of thoracic oncology and immunotherapeutics at Columbia University Medical Center discusses using PD-L1 expression on a tumor to identify patient response to treatment.
December 18, 2017 –
Community oncologists face a challenge in getting patients into clinical trials, but new technology could help them get access to those trials, explained Tesh Khullar, senior vice president of provider solutions at Flatiron Health.
December 16, 2017 –
Data needs to be more organized so it is more available and useful at the point of care, said Amy Abernethy, MD, PhD, the chief medical officer, chief scientific officer, and senior vice president of oncology at Flatiron Health.
December 12, 2017 –
Linda Schwimmer, president and CEO of the New Jersey Health Care Quality Institute, discussed the impact of data on lowering the state’s C-section rates, which are among the highest in the country.
December 05, 2017 –
On December 5, 2017, FDA approved Novo Nordisk’s semaglutide, a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes. Todd Hobbs, MD, Novo Nordisk’s vice president and chief medical officer, spoke with The American Journal of Managed Care® just ahead of FDA’s action.
December 03, 2017 –
Practices now should have at least 1 person who understands analytics, as their prevalence and importance grows in the field, explained Nat Turner, co-founder and CEO of Flatiron Health.
December 02, 2017 –
Bobby Green, MD, MSCE, senior vice president of clinical oncology at Flatiron Health discusses the future of clinical trials and how the software tool, OncoTrials, can be used to help match patients to trials.
December 01, 2017 –
Results from the FOURIER trial have provided convincing data that there is no downside to aggressively lowering cholesterol with PCSK9 inhibitors, and studies have shown there are cardiovascular benefits associated with Repatha, but reimbursement remains challenging, said Eliot A. Brinton, MD, FAHA, FNLA, president of the Utah Lipid Center.
November 30, 2017 –
Linda Schwimmer, president and CEO of the New Jersey Health Care Quality Institute, discusses the impact of the group’s report, Medicaid 2.0, which outlined how the state can bring healthcare transformation principles to a program that consumes a fifth of the state budget. New Jersey elected a new governor in November, and the blueprint was widely seen a policy recommendation for the next administration.
November 25, 2017 –
A non-fasting test to measure low-density lipoprotein (LDL) cholesterol has many advantages for patients and physicians, but payers can also see some benefits, explained Eliot A. Brinton, MD, FAHA, FNLA, president of the Utah Lipid Center.